Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. - Wikidata - wikimedia - TriplyDB

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials.

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials.

http://www.wikidata.org/entity/Q36603337

about

Emerging therapies and challenges in spinal muscular atrophy Spontaneous Breathing Pattern as Respiratory Functional Outcome in Children with Spinal Muscular Atrophy (SMA)Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool.Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy.The clinical landscape for SMA in a new therapeutic era.Longitudinal characterization of biomarkers for spinal muscular atrophy.Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain.Treatment Advances in Spinal Muscular Atrophy.Vibration-Assisted Home Training Program for Children With Spinal Muscular Atrophy.Ambulatory function in spinal muscular atrophy: Age-related patterns of progression.A New Method for Measuring Bell-Shaped Chest Induced by Impaired Ribcage Muscles in Spinal Muscular Atrophy Children

P2860

Q33578135-87B52535-3D47-4C43-BAC7-C3252F9E35FD Q36184477-5D0E41BA-0B1F-49D5-A3C2-CDB020B81703 Q36286233-DFF6E2DC-5B62-4202-8372-EFED28F76E6B Q36288904-2E8D1210-6DE0-4170-BF31-B5C194B18C26 Q38667538-C64FCAAB-346D-4C8B-BB34-FA1EF449A4D5 Q38685408-48B28347-53C9-4677-950E-0217BBC95B16 Q41461027-10BC907C-005A-430A-A789-0F624BC99599 Q45872838-F5FC859F-E28C-427A-8EB5-CF7262CC4ADE Q55425729-3D3CDA61-AC9D-473E-B827-ECF8A0996FCF Q55512456-0EC02EC5-0545-4FF7-A45B-BF2AA4A9CF6B Q57110950-D6E2FE3F-9798-4FC7-B37C-5B06F98B72BD

P2860

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials.

http://www.wikidata.org/entity/Q36603337

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials.

@ast

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials.

@en

type

label

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials.

@ast

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials.

@en

prefLabel

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials.

@ast

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials.

@en

P1433

Q36603337-08BE8B0A-D514-41E1-8D61-FCD4F6E2CF66

P1476

Q36603337-60C9A520-7999-4C81-B60C-C3EEE80F0BE1

P2093

Q36603337-0AE45107-0C9E-4B8F-AA7F-B9A048ACDE12

Q36603337-124EFD05-ADEE-4DC3-B148-AEF328908CD0

Q36603337-14631DFE-F213-4523-9CEA-1566728C6CD4

Q36603337-24EDC29A-59CD-4DE4-8421-454841BE27F4

Q36603337-2E07C7CB-3F27-422A-A55B-5834F0AC7F04

Q36603337-315D9E9F-9F87-4F0A-ACD4-E6C97C0F6C67

Q36603337-32A96BD2-ACC1-4002-A3BE-F7660776889A

Q36603337-431059E2-4AB8-40F6-ABCA-061ED6B2943C

Q36603337-48864504-920C-40B3-AC13-AE7B25B5D5A1

Q36603337-4F519C50-C418-4E18-A25F-DE3EF5477BF9

P2860

Q36603337-088D66ED-1D6B-48EF-B344-84E4B25E5D38

Q36603337-0F6A8218-05D4-470E-86FE-4206CA0A9A9F

Q36603337-12D30C07-C92E-40E2-9146-EFC5A12D8ABF

Q36603337-1D4C69DD-AC32-4A33-87F0-F036D0493745

Q36603337-24CD9036-02A9-4469-B6A2-2242F2834228

Q36603337-31DE6D38-90C3-4B21-825E-026B24831C9A

Q36603337-3BEF5D31-6FDA-427A-9D15-0C84398D63E7

Q36603337-420FFCD2-DA0B-4C50-B322-949ED3B6A20E

Q36603337-613482A8-056C-416D-8C26-CC1DD2D64AF7

Q36603337-6D9A631B-61B0-4F16-A1D8-B82B03A7482C

P304

Q36603337-0A0BA178-EF04-4294-A7FE-E16E7FE792F3

P31

Q36603337-5BAD6E1A-E9A6-479E-B4A9-6C1D9E3BCF3C

P356

Q36603337-FA3A8048-E11F-4EF6-A62D-D43A7A5F6E34

P433

Q36603337-9BD1CA72-02DB-4EA0-B2C0-D58079C5372F

P478

Q36603337-DF026B20-D38A-4F48-8056-9E05BEB3276B

P50

Q36603337-1017C449-01FA-4454-A0ED-2E406D3D32A7

Q36603337-17DC4F3E-7443-414A-B6FF-00CCE9FA7968

Q36603337-8D203328-27B5-4D46-BEC0-3C26F2379B0D

Q36603337-9532B341-84A0-4821-8DF4-68963EF84B0D

Q36603337-C827518D-6389-42E5-8C65-826771314460

Q36603337-D7EA27E0-F91E-449A-812F-87DC97AC63C9

Q36603337-EBAE96D7-95D8-4851-B75D-5A723177945B

P577

Q36603337-1C24382A-25EE-456E-8FE7-FE7030640195

P698

Q36603337-248FF703-105F-4D6B-9D8D-EA36537FAD02

P932

Q36603337-8B526785-4474-4C58-801A-398AB5B7F163

P356

J.NMD.2015.10.006

P1433

Neuromuscular Disorders

P1476

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials

@en

P2093

Adele D'Amico

http://www.w3.org/2001/XMLSchema#string

Allan M Glanzman

http://www.w3.org/2001/XMLSchema#string

Amy Pasternak

http://www.w3.org/2001/XMLSchema#string

Anna Mayhew

http://www.w3.org/2001/XMLSchema#string

Darryl C De Vivo

http://www.w3.org/2001/XMLSchema#string

Elena S Mazzone

http://www.w3.org/2001/XMLSchema#string

Francesco Muntoni

http://www.w3.org/2001/XMLSchema#string

Gian Luca Vita

http://www.w3.org/2001/XMLSchema#string

Jacqueline Montes

http://www.w3.org/2001/XMLSchema#string

Janet Quigley

http://www.w3.org/2001/XMLSchema#string

P2860

SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy

An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients

A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy

Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy

Daily salbutamol in young patients with SMA type II

Phase II open label study of valproic acid in spinal muscular atrophy

Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy

Adiposity is increased among high-functioning, non-ambulatory patients with spinal muscular atrophy

Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy.

Prospective cohort study of spinal muscular atrophy types 2 and 3.

P304

126-131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NMD.2015.10.006

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Maria Carmela Pera

Danielle Ramsey

Eugenio Mercuri

P577

2015-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26776503

http://www.w3.org/2001/XMLSchema#string

P932

4762230

http://www.w3.org/2001/XMLSchema#string